These data suggested that a vaccination-related transient disruption in immune tolerance may contribute to a reduction in BCR-ABL transcripts, and this BCR-ABL peptide vaccine may transiently improve the molecular response in a subset of patients with CML. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.